Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of finerenone in preparation of drugs for treatment of senile calcific valvular heart diseases

A valvular disease and drug technology, which is applied in the application field of finerenone in the preparation of a drug for treating senile calcific valvular heart disease, can solve problems such as undisclosed finerenone senile calcific valvular heart disease, and achieves reduction of various indicators, Improve the quality of life and improve the effect of disease

Inactive Publication Date: 2019-10-15
HUISHENG MEDICAL TECH XUZHOU CO LTD
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It can be seen that the existing patents do not disclose that finerenone can treat senile calcific heart valve disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of finerenone in preparation of drugs for treatment of senile calcific valvular heart diseases
  • Application of finerenone in preparation of drugs for treatment of senile calcific valvular heart diseases
  • Application of finerenone in preparation of drugs for treatment of senile calcific valvular heart diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Example 1 Experimental Research on the Protective Effect of Finerenone on Myocardium of Rats

[0026] 1. Materials and methods

[0027] 1.1 Experimental method

[0028] Male white rabbits with big ears were randomly divided into three groups: A (n=8), B (n=8), and C (n=8). Groups A and B were ligated to replicate the myocardial infarction model, and group C was threaded but not ligated. Group A was given finerenone (20mg·kg -1 d -1 After 1 week, the myocardial cell apoptosis index (AI) and the expressions of type Ⅰ and type Ⅲ collagen fibrils (Coll-Ⅰ, Coll-Ⅲ) in the non-infarct area of ​​each group were compared. The hemodynamic indexes [mean systolic pressure (MSP), mean diastolic pressure (MDP), mean arterial pressure (MAP), isovolumic systolic / diastolic index (±dp / dtmax)] of the aorta and left ventricle were compared. Measure and compare changes in aldosterone concentration.

[0029] 1.2 Statistical methods

[0030] All the data are represented by x±s, the comp...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a novel use of drugs and particularly discloses an application of finerenone in preparation of drugs for treatment of senile calcific valvular heart diseases. Studiesshow that finerenone is a third-generation aldosterone receptor antagonist with strong affinity for mineralocorticoids, antagonizes a series of pathological processes caused by excessive activation ofthe mineralocorticoids by aldosterone by competitively binding mineralocorticoid receptor (MR), thus regulates cell proliferation, differentiation and apoptosis, significantly improves degenerative changes of heart valve connective tissues, fibrosis, thickening and calcification, and protects cardiomyocytes. Compared with the prior art, the finerenone can reduce various indexes of senile patientswith the calcific valvular heart diseases, improves disease conditions, and improves life quality of the senile patients with the calcific valvular heart diseases.

Description

technical field [0001] The invention relates to a new application of finerenone, in particular to the application of finerenone in medicine for senile calcific heart valve disease. Background technique [0002] With the prolongation of life expectancy and the greatly reduced incidence of acute rheumatic fever, the incidence of elderly calcific valvular heart disease and its proportion in the disease spectrum have increased significantly. With the advancement of diagnostic methods such as ultrasound diagnostics, making It is possible to obtain a diagnosis of the disease before death. [0003] More than 90% of aortic stenosis in the elderly aged 65 and over is caused by aortic valve calcification, and about 52% of aortic insufficiency. Domestic reports have shown that the incidence of calcific valvular heart disease in the elderly is about 3.64%, and that of those over 60 years old is 8.62%. This cause of heart valve disease in the elderly accounts for the first place. It ac...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4375A61K45/06A61K31/40A61K31/505A61K31/47A61K31/4709A61K38/05A61P9/00
CPCA61K31/4375A61K45/06A61K31/40A61K31/505A61K31/47A61K31/4709A61K38/05A61P9/00
Inventor 何松繁
Owner HUISHENG MEDICAL TECH XUZHOU CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com